Document:

EX-4.1

 Exhibit 4.1 

[FORM OF FACE OF 11.125% MANDATORY CONVERTIBLE PREFERRED STOCK, SERIES A] 

[INCLUDE FOR GLOBAL PREFERRED SHARES] 

UNLESS THIS CERTIFICATE IS PRESENTED BY AN AUTHORIZED REPRESENTATIVE OF THE DEPOSITORY TRUST CORPORATION, A NEW YORK CORPORATION
(“DTC”), TO THE CORPORATION OR THE TRANSFER AGENT NAMED ON THE FACE OF THIS CERTIFICATE, AND ANY CERTIFICATE ISSUED IS REGISTERED IN THE NAME OF CEDE & CO. OR IN SUCH OTHER NAME AS IS REQUESTED BY AN AUTHORIZED
REPRESENTATIVE OF DTC (AND ANY PAYMENT IS MADE TO CEDE & CO., OR TO SUCH OTHER ENTITY AS IS REQUESTED BY AN AUTHORIZED REPRESENTATIVE OF DTC), ANY TRANSFER, PLEDGE OR OTHER USE HEREOF FOR VALUE OR OTHERWISE BY OR TO ANY PERSON IS WRONGFUL
IN AS MUCH AS THE REGISTERED OWNER HEREOF, CEDE & CO., HAS AN INTEREST HEREIN. 
 TRANSFERS OF THIS GLOBAL SECURITY SHALL BE
LIMITED TO TRANSFERS IN WHOLE, BUT NOT IN PART, TO NOMINEES OF DTC OR TO A SUCCESSOR THEREOF OR SUCH SUCCESSOR’S NOMINEE AND TRANSFERS OF PORTIONS OF THIS GLOBAL SECURITY SHALL BE LIMITED TO TRANSFERS MADE IN ACCORDANCE WITH THE RESTRICTIONS
SET FORTH IN THE STATEMENT WITH RESPECT TO SHARES. IN CONNECTION WITH ANY TRANSFER, THE HOLDER WILL DELIVER TO THE TRANSFER AGENT NAMED ON THE FACE OF THIS CERTIFICATE SUCH CERTIFICATES AND OTHER INFORMATION AS SUCH TRANSFER AGENT MAY REASONABLY
REQUIRE TO CONFIRM THAT THE TRANSFER COMPLIES WITH THE FOREGOING RESTRICTIONS. 

  
 1 

			
	Certificate Number [ ]		 [Initial] Number of Shares of Series A

Preferred Stock [ ]

 CUSIP 35906A 207 

ISIN US35906A2078 
 FRONTIER
COMMUNICATIONS CORPORATION 
 11.125% Mandatory Convertible Preferred Stock, Series A 

(par value $0.01 per share) 

(initial liquidation preference $100.00 per share) 

FRONTIER COMMUNICATIONS CORPORATION, a Delaware corporation (the “Corporation”), hereby certifies that [ ] / [Cede &
Co.] (the “Holder”), is the registered owner of [ ( )] / [the number shown on Schedule I hereto of] fully paid and non-assessable shares of the Corporation’s designated 11.125% Mandatory Convertible Preferred Stock, Series A,
par value $0.01 per share, initial liquidation preference of $100.00 per share (the “Series A Preferred Stock”). The shares of Series A Preferred Stock are transferable on the books and records of the Registrar, in person or by a
duly authorized attorney, upon surrender of this certificate duly endorsed and in proper form for transfer. The designations, rights, privileges, restrictions, preferences and other terms and provisions of the Series A Preferred Stock represented
hereby are, and shall in all respects be subject to the provisions of the Certificate of Designations dated June 10, 2015 as the same may be amended from time to time (the “Certificate of Designations”). Capitalized terms used
herein but not defined shall have the meaning given them in the Certificate of Designations. The Corporation will provide a copy of the Certificate of Designations to a Holder without charge upon written request to the Corporation at its principal
place of business. 
 Reference is hereby made to select provisions of the Series A Preferred Stock set forth on the reverse hereof, and to
the Certificate of Designations, which select provisions and the Certificate of Designations shall for all purposes have the same effect as if set forth at this place. 

Upon receipt of this executed certificate, the Holder is bound by the Certificate of Designations and is entitled to the benefits thereunder.

 Unless the Registrar has properly countersigned this share certificate representing the shares of Series A Preferred Stock, such shares
of Series A Preferred Stock shall not be entitled to any benefit under the Certificate of Designations or be valid or obligatory for any purpose. 

  
 2 

 IN WITNESS WHEREOF, this certificate has been executed on behalf of the Corporation by the
undersigned officers of the Corporation this [ ] day of [ ], [ ]. 
  

			
	FRONTIER COMMUNICATIONS CORPORATION
		
	By:		  

	Name:		
	Title:		

  
 3 

 REGISTRAR’S COUNTERSIGNATURE 

These are shares of Series A Preferred Stock referred to in the within-mentioned Certificate of Designations. 

Dated: [ ] 
  

			
	 COMPUTERSHARE TRUST COMPANY,
 N.A.,
as Registrar

		
	By:		  

	Name:		
	Title:		

  
 4 

 [FORM OF REVERSE OF CERTIFICATE FOR 

11.125% MANDATORY CONVERTIBLE PREFERRED STOCK, SERIES A] 

Cumulative dividends on each share of Series A Preferred Stock shall be payable subject to the terms and conditions of, in the manner and at
the applicable rate provided in the Certificate of Designations. 
 The shares of Series A Preferred Stock shall be convertible into shares
of common stock, par value $0.01 per share, of the Corporation or Units of Exchange Property, as the case may be, in the manner and in accordance with the terms set forth in the Certificate of Designations. 

The Corporation shall furnish without charge to each holder who so requests a summary of the authority of the board of directors to determine
variations for future series within a class of stock and the designations, limitations, preferences and relative, participating, optional or other special rights of each class or series of share capital issued by the Corporation and the
qualifications, limitations or restrictions of such preferences and/or rights. 

  
 5 

 NOTICE OF CONVERSION 

(To be Executed by the Holder in order to Convert the 11.125% Mandatory Convertible Preferred Stock, Series A) 

The undersigned hereby irrevocably elects to convert (the “Conversion”)
[            ] shares of 11.125% Mandatory Convertible Preferred Stock, Series A (the “Series A Preferred Stock”), of Frontier Communications Corporation (the
“Corporation”), represented by stock certificate No(s). [            ] (the “Series A Preferred Stock Certificate(s)”), into shares of common stock, par
value $0.01 per share, of the Corporation (the “Common Stock”) according to the conditions of the Certificate of Designations establishing the terms of the Series A Preferred Stock (the “Certificate of
Designations”), as of the date written below. If shares of Common Stock are to be issued in the name of a person other than the undersigned, the undersigned shall pay all transfer taxes payable with respect thereto, if any. Each Series A
Preferred Stock Certificate (or evidence of loss, theft or destruction thereof) is attached hereto. 
 Capitalized terms used but not
defined herein shall have the meanings ascribed thereto in or pursuant to the Certificate of Designations. 
 Date of Conversion: 

Applicable Conversion Rate: 
 Number of Series A Preferred Stock
to be Converted: 
 Shares of Common Stock to be Issued:* 

Signature: 
 Name: 

Address:** 
 Fax No.: 

 

	*	The Corporation is not required to issue shares of Common Stock until the original Series A Preferred Stock Certificate(s) (or evidence of loss, theft or destruction thereof) to be converted are received by the
Corporation or the Conversion and Dividend Disbursing Agent. 

	**	Address where shares of Common Stock and any other payments or certificates shall be sent by the Corporation. 

  
 6 

 ASSIGNMENT 

FOR VALUE RECEIVED, the undersigned assigns and transfers the shares of Series A Preferred Stock evidenced hereby to: 

(Insert assignee’s social security or taxpayer identification, if any) 

(Insert address and zip code of assignee) 

(Insert assignee’s social security or taxpayer identification, if any) 

and irrevocably appoints: 
 as agent to transfer the shares of
Series A Preferred Stock evidenced hereby on the books of the Transfer Agent. The agent may substitute another to act for him or her. 
 Date: 

Signature: 
 (Sign exactly as your name appears on the other
side of this Certificate) 
 Signature 
 Guarantee: 

(Signature must be guaranteed by an “eligible guarantor institution” that is a bank, stockbroker, savings and loan association or
credit union meeting the requirements of the Transfer Agent, which requirements include membership or participation in the Securities Transfer Agents Medallion Program (“STAMP”) or such other “signature guarantee program”
as may be determined by the Transfer Agent in addition to, or in substitution for, STAMP, all in accordance with the Securities Exchange Act of 1934, as amended.) 

  
 7 

 Schedule I1 

Frontier Communications Corporation 

Global Preferred Share 

11.125% Mandatory Convertible Preferred Stock, Series A 

Certificate Number: [    ] 
 The number of
shares of Series A Preferred Stock initially represented by this Global Preferred Share shall be . Thereafter the Transfer Agent and Registrar shall note changes in the number of shares of Series A Preferred Stock evidenced by this Global Preferred
Share in the table set forth below: 
  

							
	 Amount of

Decrease
 in Number of

Shares
 Represented by this

Global Preferred
 Share
		 Amount of Increase
in Number of
Shares
Represented by
this
Global Preferred
Share
		 Number of Shares
Represented by this
Global
Preferred
Share following
Decrease or
Increase
		 Signature of
Authorized Officer
of Transfer Agent
and
Registrar

	  
		  
		  
		  

	  
		  
		  
		  

	  
		  
		  
		  

  

	1 	Attach Schedule I only to Global Preferred Shares. 

  
 8Exhibit 10.1

 

SEPARATION AGREEMENT AND GENERAL RELEASE

 

Rock Creek Pharmaceuticals,
Inc., a Delaware corporation (hereinafter "Employer" or “Company”), and Christopher C. Chapman, MD, his heirs,
executors, administrators, successors, and assigns (collectively referred to throughout this Agreement as "Employee"),
agree to and intend to be legally bound by the following:

 

1.Last Day of
Employment.

 

a.Employee
has elected to voluntarily resign his employment and all offices and directorships he holds with the Employer. Employee's last
day of employment with Employer will be June 30, 2105, provided that during the period after the date of this Agreement and continuing
through and including June 30, 2015 (the “Transition Period”), Employee shall be relieved of his general day-to-day
duties, and his employment duties during the Transition Period will be limited to being available to the Employer for telephone
and email consultations regarding transition matters at the request of Employer. The telephone and email consultations during the
Transition Period shall be requested by the Company upon reasonable advance notice and in a manner so as not to unreasonably interfere
with other commitments of Employee.

 

b.Employee
and Employer agree that the Employment Agreement, dated December 27, 2013, between Employer (f/k/a Star Scientific, Inc.) and Employee
(the “Employment Agreement”) shall be terminated effective as of the date of this Agreement, and neither the Employer
nor the Employee shall have any further rights or obligations thereunder other than as specifically set forth in this Separation
Agreement and General Release (this “Agreement”). In addition to the amounts specified in Paragraph 2 below, Employer
will pay Employee, at the base salary rate of $300,000 per year, for all work performed through Employee’s last day of employment,
less any lawful deductions, all in accordance with its normal payroll practices, or sooner if required by law, and Employer will
continue to be entitled to his current medical benefits and life insurance coverage through the last day of employment.

 

c.Employee
hereby resigns, effective as of the date of this Agreement, from all officer and director positions held by him with the Employer
and its subsidiaries and affiliates, including without limitation from the offices of President and Director of the Employer. Employer
acknowledges and agrees that the separation of Employer is a voluntary separation and is not a termination for “Cause”
under the terms of the Employment Agreement.

 

2.Consideration.
In consideration for signing this Separation Agreement and General Release (this "Agreement") and in consideration of
Employee's adherence to the promises made herein, Employer agrees that:

 

a.Commencing
on July 1, 2015, Employer will pay Employee severance in an amount equivalent to $25,000 per month payable for three (3) months
through and including September 30, 2015. All such payments to Employee shall be made in accordance with the Employer’s regular
payroll schedule and be subject to all legally required withholdings and taxes. However, no such payments shall be made to Employee
any sooner than eight (8) days following his execution of the Employee Reaffirmation set forth on the last page of this Agreement
(which Employee Reaffirmation shall be executed and delivered to the Company no earlier than July 1, 2015).

 

    	 

    	 

    

 

b. On
or before the end of the tenth (10th) trading day after the date of this Agreement, Employee shall be issued shares
of the Company’s common stock, par value $.0001 per share, in satisfaction of an aggregate of $51,346.11 in base salary that
was previously accrued but not paid to Employee (“Unpaid Salary”). The number of shares that will be issued to Employee
will equal the amount of Unpaid Salary divided by the closing price of the Company’s common stock on the Nasdaq Capital Market
on the trading day immediately preceding the date of issuance (with any fractional shares being rounded up to the next whole share).

 

c.All
benefits and accruals will cease as of June 30, 2015. Effective July 1, 2015, Employee shall be eligible to continue his group
medical insurance benefits under the terms and conditions of the federal law commonly known as “COBRA.”

 

3.No Consideration
Absent Execution of this Agreement. Employee understands and agrees that Employee would not receive the benefits specified
in Paragraphs 2(a) through (c) above, except for Employee's execution of this Agreement and the fulfillment of the promises contained
herein.

 

4.General Release
of Claims. Employee knowingly and voluntarily releases and forever discharges Employer, its parent, affiliates, subsidiaries,
divisions, predecessor companies, their successors and assigns, their affiliated and predecessor companies and the current and
former employees, attorneys, shareholders, members, officers, directors, managers and agents thereof and the current and former
trustees or administrators of any pension or other benefit plan applicable to the employees or former employees of Employer (collectively
referred to throughout the remainder of this Agreement as "Releasees"), of and from any and all claims, demands, liabilities,
obligations, promises, controversies, damages, rights, actions and causes of action, known and unknown, which the Employee has
or may have against Releasees as of the date of execution of this Agreement, including without limitation any allegations of breach
of contract or unlawful discrimination, as well as any alleged violation of or claims relating to or arising under:

 

Title VII of the Civil
Rights Act of 1964, as amended;

 

The Civil Rights Act
of 1991;

 

Sections 1981 through
1988 of Title 42 of the United States Code, as amended;

 

The Employee Retirement
Income Security Act of 1974, as amended;

 

The Americans with
Disabilities Act of 1990, as amended;

 

    	2

    	 

    

 

The Age Discrimination
in Employment Act;

 

The Occupational Safety
and Health Act, as amended;

 

The Consolidated Omnibus
Budget Reconciliation Act of 1985;

 

The Virginia Human
Rights Act;

 

Any other federal,
state or local civil or human rights law or any other federal, local, or state cause of action alleging violation of public policy,
contract, tort, or common law; or

 

Any allegation for
costs, fees, or other expenses including attorneys' fees incurred in these matters (all of the above collectively referred to as
"Claims").

 

This release is intended
to be a general release, and excludes only those claims under any statute or common law that Employee is legally barred from releasing.
Employee is advised to seek independent legal counsel if Employee needs clarification on the scope of this release.

 

The release in this
Paragraph 4 is intended to be a general release, and excludes only those claims under any statute or common law that Employee is
legally barred from releasing.

 

Nothing in this Agreement
is intended to or shall prevent Employee from: a) filing a charge of discrimination with the U.S. Equal Employment Opportunity
Commission or any federal, state, or local government agency and/or cooperating with any such agency in any investigation or b)
to challenge the knowing and voluntary nature of the waivers and releases contained in this Agreement. Employee, however, explicitly
waives any right to file a personal lawsuit, and similarly waives any right to receive monetary damages that the agency may recover
against Releasees, without regard as to who brought any said complaint or charge.

 

5.Affirmations.
Employee represents and agrees by signing below that Employee has no known workplace injuries or occupational diseases and that
Employee has not filed, nor has Employee caused to be filed, nor is Employee presently a party to any claim, complaint, or action
against Releasees in any forum or form. Other than the consideration set forth in Paragraphs 2(a) through (c), Employee affirms
that Employee has been paid and/or has received all leave (paid or unpaid), compensation, wages, bonuses and/or commissions to
which Employee may be entitled and that no other leave (paid or unpaid), compensation, wages, bonuses and/or commissions are due
to Employee. Furthermore, Employee acknowledges that while employed with Employer and as of the date of this Agreement, Employee
knows no fact, evidence, or information that would lead Employee to allege a violation of any rule, law or regulation against Employer,
its affiliates, related companies, or any employees other person or entity, or any of them.

 

6.Survival of
Provisions of Employment Agreement. Notwithstanding anything to the contrary set forth in this Agreement, Section 5 (Restriction
on Competition) and Section 6 (Confidential Information) of the Employment Agreement shall survive the termination of the Employment
Agreement and shall hereafter remain in full force and effect. However, the Company agrees that, for purposes of Section 5 of the
Employment Agreement, developing, marketing, commercializing, or selling a pharmaceutical product shall not be deemed to be “competitive”
with the business of the Company or its affiliates unless such activity involves Anatabine or a substantially similar molecule
in some manner or unless it involves intellectual property or proprietary information owned or licensed by the Company or its affiliates.

 

    	3

    	 

    

 

7.Governing
Law and Interpretation. This Agreement shall be governed by and construed in accordance with the laws of the State of Florida
without giving effect to the principles of conflicts of law. Employee hereby irrevocably submits to the personal and exclusive
jurisdiction of the United States District Court for the Middle District of Florida or the Courts of the State of Florida located
within Hillsborough County and Sarasota County, Florida in any action or proceeding arising out of, or relating to, this Agreement
(whether such action arises under contract, tort, equity or otherwise.) Employee hereby irrevocably waives any objection which
Employee now or hereafter may have to the laying of venue or personal jurisdiction of any such action or proceeding brought in
said courts. Jurisdiction and venue of all such causes of action shall be exclusively vested in the United States District Court
for the Middle District of Florida or the Courts of the State of Florida located within Hillsborough County and Sarasota County,
Florida. Employee irrevocably waives Employee's right to object to or challenge the above selected forum on the basis of inconvenience
or unfairness under 28 U.S.C. § 1404, or similar state or federal statutes.

 

8.Return of
Employer Property. Employee agrees that as a condition for receiving any of the benefits described in Paragraph 2 above, he
will return, by the last day of the Transition Period, any and all of Employer's property currently in Employee's possession including
any documents, reports, manuals, keys, credit cards, security cards and passwords, and any other company documents or property
whether stored electronically or otherwise. Employee agrees that he shall not keep copies of any company documents or information.

 

9.Stock Options.
The parties acknowledge and agree that (i) nothing set forth in this Agreement will affect the vested stock options previously
granted to Employee under Section 2.3(a)(i) of the Employment Agreement, which options currently represent the right to purchase
20,000 shares of Company common stock (after giving effect to the Company’s reverse stock split in April 2015) and which
options shall continue to be exercisable through the expiration date thereof in accordance with the terms of the applicable stock
option agreement and the Company’s 2008 Incentive Award Plan, as amended, (ii) the stock options previously granted pursuant
to Section 2.3(a)(ii) of the Employment Agreement have not vested and are hereby terminated, and (iii) nothing set forth in this
Agreement will affect the vested stock options previously granted to Employee on various dates beginning on September 22, 2005
and continuing through and including September 22, 2013, by reason of Employee’s service as a director of the Company, such
options representing the right to purchase an aggregate of 23,000 shares (after giving effect to the Company’s April 2015
reverse stock split), which options shall continue to be exercisable in accordance with the terms of the applicable award agreement
and applicable stock incentive plan.

 

10.Release of
Employee. Employer hereby knowingly and voluntarily releases and forever discharges Employee from any and all claims and
causes of action of which the Employer has knowledge as of the date that the Employer signs this Agreement. Employer will not be
deemed to have knowledge of a claim or cause of action for purposes of the preceding sentence unless one or more Specified Persons
(as defined below) has actual conscious knowledge, as of the date on which the Employer executes this Agreement, of specific facts
or circumstances which the Specified Person knows or should reasonably know gives rise to a legal claim or cause of action against
Employee. For purposes hereof, the term “Specified Person” means the following directors and/or senior executive officers
of the Company: Michael A. Mullan, Lee M. Canaan, Scott Sensenbrenner, Suni Chundru, Ted Jenkins, and Benjamin M. Dent.

 

    	4

    	 

    

 

11.Consulting
Services. Employee agrees that, during the period beginning on July 1, 2015 and continuing through and including December 31,
2015 (the “Consulting Term”), Employee shall, at the request of the Company, provide consulting services to Company
and its subsidiaries on an as-needed and as-requested basis, with such consulting services to consist of answering questions and
otherwise assisting the Company with transition, regulatory, and drug development matters, as well as other corporate matters with
which Employee is familiar by reason of him having served as President of the Company. Such consulting services shall be provided
only by email or telephone and upon reasonable advance notice so as not to interfere with Employee’s prior commitments or
plans, and the consulting services will not exceed five (5) hours per calendar month unless Employee agrees otherwise. Company
will not be obligated to utilize or request the consulting services. If any consulting services are provided, Company will pay
Employee a consulting fee equal to $300 for each half day of services provided. The consulting services will be rendered as an
independent contractor and not as an employee of the Company.

 

12.Severability.
If any term, provision or paragraph of this Agreement is determined by a court of competent jurisdiction to be invalid or unenforceable
for any reason, such determination shall be limited to the narrowest possible scope in order to preserve the enforceability of
the remaining portions of the term, provision or paragraph, and such determination shall not affect the remaining terms, provisions
or paragraphs of this Agreement, which shall continue to be given full force and effect.

 

13.Mutual
Non-Disparagement.

 

a.Except
as otherwise required by law or compelled by a court of competent jurisdiction, Employee will not, directly or indirectly,
make any statements, engage in any conduct, or create, author, issue, publish or disseminate any communication (including, without
limitation, to Company’s stockholders, vendors, customers, partners, directors, officers, employees, or other third parties)
that could be constructed by a reasonable person to be derogatory, disparaging, embarrassing, or negative as to Company or any
of its officers, directors, or employees or that to any extent damages or interferes with the business and affairs of Company or
any of its officers or directors, or impairs the good will, business reputation or good name of any of them.  This prohibition
shall apply to all communication or conduct of any type, whether oral or written, without regard to the particular medium or media
in which such communication or conduct occurs.  Employee acknowledges that he has no authority to speak for or act as a representative
of Company or any of its Affiliates.

 

    	5

    	 

    

 

b.Except
as otherwise required by law or compelled by a court of competent jurisdiction, Company will not directly or indirectly make any
statements, engage in any conduct, or create, author, issue, publish or disseminate any communication that could be constructed
by a reasonable person to be derogatory, disparaging, embarrassing, or negative as to Employee which impairs his business
reputation or good name.  This prohibition shall apply to all communication or conduct of any type, whether oral or written,
without regard to the particular medium or media in which such communication or conduct occurs.  The Company shall have no
liability under this paragraph for internal discussions among its directors, officers, or employees made in good faith, nor will
the Company have any liability under this paragraph for statements made in good faith that are reasonably necessary or helpful for
the defense or prosecution of any legal dispute or otherwise made in good faith in connection with any regulatory matter or inquiry.

 

14.Non-admission
of Wrongdoing. The parties agree that neither this Agreement nor the furnishing of the consideration for this Agreement shall
be deemed or construed at any time for any purpose as an admission by Employer, or evidence of any liability or unlawful conduct
of any kind. Employer acknowledges that Employee’s separation from the Company is not a termination for “Cause”
within the meaning of the Employment Agreement.

 

15.Amendment.
This Agreement may not be modified, altered or changed except in writing and signed by both parties wherein specific reference
is made to this Agreement.

 

16.Entire Agreement.
No prior or contemporaneous oral or written agreements or representations may be offered to alter the terms of this Agreement which
represents the entire agreement of the parties with respect to the subject matter hereof.

 

17.Signatures.
This Agreement may be executed in counterparts, any such copy of which to be deemed an original, but all of which together shall
constitute the same instrument.

 

18.Assignment.
Employer and Releasees have the right to assign this Agreement, but Employee does not. This Agreement inures to the benefit of
the successors and assigns of the Employer, who are intended third party beneficiaries of this Agreement.

 

19.Notice to
Employee.Employee is been advised to consult with an attorney prior to executing this Agreement; that he in fact has
consulted with his attorney Drew Clayton, Esq. regarding this Agreement; that he may, before executing this Agreement, consider
this Agreement for a period of 21 calendar days; and that the consideration he receives for this Agreement is in addition to amounts
to which he was already entitled. Employee agrees that any modifications, material or otherwise made to this Agreement shall not
restart or affect the twenty-one day consideration period. It is further understood that this Agreement is not effective until
seven calendar days after the execution of this Agreement and that the Executive may revoke this Agreement within seven calendar
days from the date of execution hereof by submitting written notice of his intent to revoke and delivering it to the outside counsel
of the Company (Curt Creely at Foley & Lardner LLP) on or before the seventh day following execution. 

 

    	6

    	 

    

 

EMPLOYEE FREELY AND KNOWINGLY ENTERS
INTO THIS AGREEMENT INTENDING TO WAIVE, SETTLE AND RELEASE ALL RELEASABLE CLAIMS, INCLUDING CLAIMS OF AGE DISCRIMINATION THAT EMPLOYEE
HAS OR MIGHT HAVE AGAINST EMPLOYER.

 

 

 

 

 

[rest of page intentionally left blank]

 

    	7

    	 

    

 

 

IN WITNESS WHEREOF, the parties hereto
knowingly and voluntarily executed this Agreement as of the dates set forth below, with the date of this Agreement to be deemed
the latest date executed by a party hereto.

 

	ROCK CREEK PHARMACEUTICALS, INC.	 	EMPLOYEE	 
	 	 	 	 	 
	By:	/s/ Michael J. Mullan	 	/s/ Christopher C. Chapman	 
	 	Michael J. Mullan, Chief Executive Officer	 	Christopher C. Chapman, MD, individually	 
	 	 	 	 	 
	 	 	 	 	 
	Date:  June 9, 2015	 	Date: June 9, 2015	 
	 	 	 	 	 

 

 

    	8

    	 

    

 

 

EMPLOYEE REAFFIRMATION

 

In consideration for the payment of the
amounts set forth in Paragraph 2 of the Separation Agreement and General Release, dated June 9, 2015, between Rock Creek Pharmaceuticals,
Inc. and Christopher C. Chapman, MD and (the “Agreement”), minus all legally required withholding, I, Christopher C.
Chapman do reaffirm and acknowledge that I remain bound by all of the terms of the Agreement, including all of the releases and
waivers contained therein, which releases and waivers shall also be deemed to be made as of the date hereof.

 

 

 

 

 

	EMPLOYEE	 
	 	 
	 	 
	 	 
	Christopher C. Chapman, MD	 
	 	 
	Date: July ____, 2015	 

 

 

    	9

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00246-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00246-of-00352.parquet"}]]